Form 8-K - Current report:
SEC Accession No. 0000950170-24-089235
Filing Date
2024-08-01
Accepted
2024-08-01 16:02:10
Documents
13
Period of Report
2024-08-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-20240801.htm   iXBRL 8-K 42922
2 EX-99.1 sndx-ex99_1.htm EX-99.1 178054
3 GRAPHIC img199102934_0.jpg GRAPHIC 14374
  Complete submission text file 0000950170-24-089235.txt   372318

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sndx-20240801.xsd EX-101.SCH 25827
15 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20240801_htm.xml XML 4869
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 241166446
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)